| abstract |
Dislcosed is a method of inhibiting or reducing steroid-dependent gene activation comprising: a) providing a biological sample comprising a steroid receptor; b) administering a first compound to said biological sample, wherein said first compound induces degradation of said steroid receptor, and said first compound is selected from the group consisting of functional derivatives and functional analogues of curcumin; and c) administering a second compound to said biological sample, wherein said second compound inhibits said steroid receptor from activating a gene, and said second compound is selected from the group consisting of bicalutamide, hydroxyflutamide, docosahexaenoic acid (DHA), silibinin (SB), quercetin (QU), finesteride, dutasteride, vitamin E succinate (VES), and functional derivatives and functional analogues thereof; wherein said first compound and said second compound act at different steps within a gene activation pathway of said steroid receptor; further wherein steroid-dependent gene activation is reduced or inhibited greater than if said first compound or said second compound are administered alone. Further disclosed are pharmaceutical compositions and uses thereof. |